Marc Wilson
Vermogen: 4 M $ op 30-06-2026
Vermogen: 4 M $ op 30-06-2026
Marc J.
S.
Wilson formerly worked at Trius Therapeutics, Inc., as Accounting Director & Controller from 2010 to 2014, Cidara Therapeutics, Inc., as Chief Accounting Officer & Vice President from 2014 to 2018, and Crinetics Pharmaceuticals, Inc., as Chief Financial Officer from 2018 to 2025.
Mr. Wilson received his undergraduate degree from College of the Holy Cross (Massachusetts).
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 08-07-2026 | 105.237 ( 0,1% ) | 4 M $ | 30-06-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
| CRINETICS PHARMACEUTICALS, INC. | Financieel Directeur/CFO | 28-02-2025 |
| CIDARA THERAPEUTICS | Comptroller/Controller/Auditor | 03-01-2018 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops antibacterial drugs for the treatment of infections | Comptroller/Controller/Auditor | 01-08-2014 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
College of the Holy Cross (Massachusetts)
College of the Holy Cross (Massachusetts) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops antibacterial drugs for the treatment of infections | Health Technology |
Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Engages in the discovery, development, and commercialization of novel anti-infectives | Health Technology |
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets therapeutics for endocrine-related diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau